Talazoparib + enzalutamide in treatment of mCRPC

Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Preliminary data from the TRITON 2 trial of rucaparib in mCRPC

A poster presented at the ESMO meeting in Munich has just reported data from an unplanned, preliminary analysis of data from the first 85 patients (out of a scheduled total of 150 patients) enrolled in the TRITON 2 trial of the PARP inhibitor rucaparib (Rubraca) … READ MORE …